

### THE MS DECISIONS STUDY

# What Factors Influence Changes in MS Management? Comparing the Perspectives of Patients and Health Care Providers using Nominal Group Technique

<sup>1</sup>University of Vermont College of Medical School, <sup>5</sup>Boston University of Haalth & Rehabilitation Sciences, <sup>6</sup> University of Colorado, Denver, <sup>7</sup>Colorado Springs Neurological Associates,<sup>8</sup>Biogen, <sup>9</sup>Shared Decision Making Resources and University of New England Research supported by Biogen\*

Results

### Background

- Little is known about differences between patient or health care provider concerns that may prompt a change in the management of Multiple Sclerosis (MS).
- Incorporating patient perspectives into treatment decisions promotes shared decision-making and values-based choices.

### **Study Objectives**

To compare factors that may influence changes in the management of MS between patients with MS and health care providers.

### **Inclusion Criteria**

#### **Patients:**

- Confirmed MS diagnosis
- Age 21-75
- Web access
- Targeting racial diversity
- **HCPs:**
- Neurologist, PA, RN or NP;
- MS focus,
- Sees  $\geq$  10 MS patients/month
- National sample
- National sample

### Methods

### Nominal Group Technique (NGT):


- Structured focus group
- Elicits and prioritizes responses to a single question
- NGT Steps:
  - 1. Participants silently write down ideas to the question
- 2. Round-robin recording of ideas then group discussion
- 3. Private vote on item importance with weighted ballots
- Resulting prioritized lists of items were combined

### **NGT Questions**

- Patients were asked: "What factors would make you decide to change how you manage your MS?"
- HCPs were asked: "What factors would make you decide to change how you manage your patient's MS?"

### **Overall Study Design**

NGT Question Development (cognitive interviews)



**HCP NGT** 2 NGT groups 2 sites 15 participants

MS Patient NGT 2 NGT groups 2 sites **15 participants** 

\*Biogen reviewed the content and provided feedback. Authors had full editorial control of the poster and provided their final approval of all content.

A.J. Solomon, MD<sup>1</sup>, V. Springmann, MSc<sup>2</sup>, C. Ionete, MD, PhD<sup>3</sup>, L. Pbert, PhD<sup>4</sup>, W. Anthony, PhD<sup>5</sup>, E. Alvarez, MD, PhD<sup>5</sup>, E. Alvarez, PhD<sup>5</sup>, E. Alvarez, PhD<sup>5</sup>, E. Alvarez, PhD<sup>5</sup>, E. Alvarez, MD, PhD<sup>5</sup>, E. Alvarez, PhD<sup>5</sup>, E G.A. Phillips, PhD<sup>8</sup>, N. Col, MD, MPP, MPH<sup>9</sup>

## **Raw NGT Findings: Top 10 Factors**


#### Patients: Atlanta, GA

#### f I was getting worse gradually/progression / losing physical and mental function

- When MS is not stable (new symptoms, or not being able to manage existing...
  - A new or better treatment is available
  - If my physical activity becomes limited
  - Changes in insurance coverage
- If other people with similar MS had good results with a new DMT treatment
- If I keep having relapses The inconvenience/difficulty/cost of changing treatment (any treatment)
- Change in my career or job
- If I learn about non-DMT treatments that can help manage symptoms (e.g....
- An outside observer suggests that something has changed.

Sum Weighted Importance (%


#### Patients: Colorado Springs, CO




Changes in the severity of my symptoms

- ortance of holistic approaches (e.g. diet exercise meditation)
  - Financial challenges limit treatment /management options
- nowledge of resources available (including transportation, financial,
- The ability to pay for medication/financial challenges in obtaining the..
  - More information about new treatment options
    - If I'm starting to decline
- Provider really demonstrating changes (or not) over time, comparing meaningful
- More active support and better communication/discussion with your provider,.

### HCPs: Denver, CO



### HCPs: Colorado Springs, CO



### **Comparison of Factors Influencing Treatment** Changes, Patients versus HCPs, by Category

(Shading indicates items that were unique to either patients or HCPs)

#### **Patient Factors**

**HCP Factors** 

| lew or better treatments are available                     |   |
|--|---|
| others with similar MS had good results with a new DMT     | New treatment option/s comes out            |
| inding out about new or better treatment                   | New research findings                       |
| wareness of non-DMT treatments or holistic approaches      |   |
| ·  |   |
| ifestyle/convenience                                       |   |
| amily issues   | Detient's desire for change                 |
| convenience of changing treatment                          | Patient's desire for change                 |
| ccess to exercise equipment                                |   |
| Disease progression or relapses                            |   |
| tarting to decline /getting gradually worse                | Progression of disability                   |
| osing physical or mental function                          | Any relapses/Increased relapse rate         |
| hysical activity becomes limited                           |   |
| aving relapses or more relapses                            | MS disease progression                      |
| hange in MRI   | MRI changes/New MRI activity                |
| rovider demonstrates objective evidence of change (or not) |   |
| IS is not stable (new symptoms, unable to manage symptoms) | Identify new symptoms/ Worsening of chronic |
|  | symptoms (e.g. fatigue)                     |
| inancial concerns  |   |
| hange in financial situation                               | Insurance and financial availability        |
| hange in insurance coverage                                | Change in insurance provider                |
| hange in my career or job                                  |   |
| reatment is too expensive                                  | Treatment is too expensive                  |
| Inable to handle treatment                                 |   |
| etting tired of dealing with MS                            | Patient response to current treatment       |
| omplications or adverse effects arise from the med         | -Serious adverse event to that patient      |
| •  | -Abnormal labs/Intolerable side-effect      |
|  | -Medication allergies                       |
| ymptoms of depression / helplessness develop/worsen        |   |
|  | Pregnancy /desire to become pregnant        |
| aring and well-informed medical team                       |   |
| ore active support and better communication with provider  |   |
| aving a supporting neurologist who is well informed        |   |
| change in provider   |   |
| ledical Background   |   |
| ly age   |   |
| iagnosis of PML  | JC virus seroconversion                     |
| Support  |   |
| nowledge of resources available (transportation, \$)       |   |
| nd of a clinical trial that provides support and treatment |   |
| Other  |   |
|  | Poor tolerability                           |
|  | Lack of compliance                          |
|  | New safety concerns of a DMT                |

### **Key Findings**

- The most important factor for patients was changes in severity of symptoms/disease progression.
- The most important factors for providers were new MRI activity and progression of disability.
- Both patients and HCPs prioritized slowing disability.
- Only patients prioritized awareness of holistic approaches, availability of resources, and inconvenience.
- Only providers prioritized concerns about safety, adverse events, and non-adherence.

### Implications

- There were differences in the factors that might influence treatment changes between patients and HCPs.
- There were differences in how similar factors were articulated by both groups.
- Assessing factors that influence patient decisions about changing treatment should improve patientprovider communication and treatment management.
- Communication tools are needed to bridge communication gaps and support shared decision making in discussions about MS treatment.

### Limitations

- Recall bias
- Small sample size limits generalizability
- Cross-sectional study design

### Next Steps

Develop and validate preference assessment instrument

### References

- 1.Delbeq AI, van de Ven AH, Gustafson DH. (1975): Group Techniques for Program Planning: A Guide to Nominal and Delphi Processes. Glenview, III: Scott, Foresman Co. 2.Risk Communication Advisory Committee and consultants (2013) Communicating
- Risks and Benefits: An Evidence-Based User's Guide. Eds: Fischhoff B, Brewer NY, Downs JS. U.S. Department of Health and Human Services; FDA.
- 3. Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions (Review). The Cochrane Collaboration, Cochrane Lib 2013,(11).